



**New Drugs Reviewed by on CPG September 17, 2019  
For Drugs Released Between 4/27/2019 to 8/28/2019**

The Committee on Prescriptive Governance (CPG) meets at least twice a year to make recommendations to the Board regarding the Exclusionary Formulary. The CPG reviews new drugs that have been approved by FDA included in the *Online Drug Facts and Comparisons*. The following new drugs reviewed at the last CPG meeting were NOT added to the Exclusionary Formulary.

**NEW DRUGS NOT ADDED TO THE EXCLUSIONARY FORMULARY**

<b>Generic Name</b>	<b>Brand Name</b>
tafamidis meglumine	Vyndagel
tafamidis	Vyndamax
amifampridine	Ruzurgi
dapagliflozin/saxagliptin/metformin HCL	Qternmet XR
Dengue tetravalent vaccine, live	Dengvaxia
midazolam	Nayzilam
alpelisib	Piqray
onasemnogene abeparvovec-xioi	Zolgensma
mepolizumab	Nucala
polatuzumab vedotin-piiq	Polivy
trastuzumab-anns	Kanjinti
bremelanotide	Vyleesi
bevacizumab-bvzr	Zirabev
selinexor	Xpovio

immune globulin human-klhw	Xembify
amlodipine	Katerzia
imipenem/cilastatin/relebactam	Recarbrio
rituximab-pvvr	Ruxience
adalimumab-bwwd	Hadlima
ferric maltol	Accrufer
darolutamide	Nubeqa
pexidartinib	Turalio
pitolisant	Wakix
pretomanid	(generic only)
entrectinib	Rozlytrek
fedratinib	Inrebic
upadacitinib	Rinvoq
lefamulin	Xenleta
Ga 68 Dotatoc	Ga 68 Dotatoc
istradefylline	Nourianz